We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $2.05B
1-Year Est. Return 161.37%
This Fund
S&P 500
This Quarter Est. Return
+46.69%
1 Year Est. Return
+161.37%
3 Year Est. Return
+342.48%
5 Year Est. Return
+531.16%
10 Year Est. Return
+6,258.71%
AUM
$2.05B
AUM Growth
+$352M
Cap. Flow
-$16.5M
Cap. Flow %
-0.81%
Top 10 Hldgs %
43.96%
Holding
116
New
16
Increased
40
Reduced
31
Closed
12
Avg Time Held
10.6 quarters
Top 10 Avg Time Held
4.1 quarters
Top 20 Avg Time Held
7.1 quarters

Top Buys

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$31.1M
2
AVLN icon
Avalyn Pharma
AVLN
+$19.1M
3
PBLS
Parabilis Medicines Inc
PBLS
+$16M
4
COAG icon
Hemab Therapeutics
COAG
+$15.9M
5
CYTK icon
Cytokinetics
CYTK
+$10.2M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$37.7M
2
ACLX icon
Arcellx
ACLX
+$19.5M
3
ELVN icon
Enliven Therapeutics
ELVN
+$15.4M
4
RVMD icon
Revolution Medicines
RVMD
+$15.2M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$14M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RVMD icon
1
Revolution Medicines
RVMD
$41.3B
$207M 10.1%
1,105,210
-104,255
-9% -$15.2M
2023 Q1
13 quarters
TVTX icon
2
Travere Therapeutics
TVTX
$4.85B
$124M 6.04%
2,179,069
+701,115
+47% +$31.1M
2015 Q1
45 quarters
LLY icon
3
Eli Lilly
LLY
$1.05T
$118M 5.78%
98,700
– –
2023 Q4
10 quarters
MDGL icon
4
Madrigal Pharmaceuticals
MDGL
$10.5B
$94M 4.59%
174,999
+4,000
+2% +$2.05M
2016 Q3
39 quarters
MIRM icon
5
Mirum Pharmaceuticals
MIRM
$5.42B
$93.4M 4.56%
798,145
-13,149
-2% -$1.32M
2019 Q3
27 quarters
RYTM icon
6
Rhythm Pharmaceuticals
RYTM
$6.11B
$76.9M 3.75%
692,598
+2,850
+0.4% +$258K
2017 Q4
34 quarters
KYMR icon
7
Kymera Therapeutics
KYMR
$9.19B
$52M 2.54%
453,156
-43,715
-9% -$3.76M
2020 Q3
23 quarters
ARGX icon
8
argenx
ARGX
$51B
$48.9M 2.39%
52,750
-45,750
-46% -$37.7M
2018 Q2
32 quarters
ASND icon
9
Ascendis Pharma A/S
ASND
$14.9B
$45M 2.2%
168,750
-25,250
-13% -$5.9M
2015 Q1
45 quarters
XENE icon
10
Xenon Pharmaceuticals
XENE
$3.43B
$41.3M 2.01%
683,907
-79,113
-10% -$4.39M
2020 Q1
25 quarters
SRRK icon
11
Scholar Rock
SRRK
$5.02B
$39.3M 1.92%
715,452
-24,364
-3% -$1.18M
2024 Q4
6 quarters
INSM icon
12
Insmed
INSM
$21.6B
$38.6M 1.88%
362,150
+47,850
+15% +$5.79M
2024 Q2
8 quarters
PEN icon
13
Penumbra
PEN
$12.6B
$36.5M 1.78%
115,750
-4,750
-4% -$1.54M
2015 Q3
43 quarters
GPCR icon
14
Structure Therapeutics
GPCR
$1.66B
$34.4M 1.68%
640,317
+100
+0% +$4.42K
2023 Q4
10 quarters
RARE icon
15
Ultragenyx Pharmaceutical
RARE
$1.49B
$32.3M 1.58%
967,855
-250,918
-21% -$6.23M
2014 Q1
49 quarters
IRTC icon
16
iRhythm Holdings
IRTC
$3.49B
$32.1M 1.57%
269,650
+7,900
+3% +$918K
2017 Q3
35 quarters
ISRG icon
17
Intuitive Surgical
ISRG
$149B
$30.4M 1.48%
76,460
-5,540
-7% -$2.42M
2013 Q4
50 quarters
AGL icon
18
Agilon Health
AGL
$1.45B
$28.1M 1.37%
262,600
+2,600
+1% +$170K
2021 Q2
20 quarters
UNH icon
19
UnitedHealth
UNH
$340B
$26.5M 1.29%
63,750
+10,750
+20% +$3.98M
2025 Q4
2 quarters
CLDX icon
20
Celldex Therapeutics
CLDX
$2.27B
$26M 1.27%
699,146
+48,876
+8% +$1.58M
2022 Q1
17 quarters
ERAS icon
21
Erasca
ERAS
$5.38B
$25.7M 1.25%
1,402,150
+298,681
+27% +$4.27M
2025 Q4
2 quarters
NBIX icon
22
Neurocrine Biosciences
NBIX
$14B
$24.4M 1.19%
144,750
-5,700
-4% -$846K
2014 Q1
49 quarters
ELVN icon
23
Enliven Therapeutics
ELVN
$2.97B
$23.6M 1.15%
464,625
-361,875
-44% -$15.4M
2024 Q1
9 quarters
THC icon
24
Tenet Healthcare
THC
$21.6B
$23.4M 1.14%
125,000
– –
2024 Q4
6 quarters
DXCM icon
25
DexCom
DXCM
$32.1B
$23.1M 1.13%
343,000
-12,600
-4% -$839K
2021 Q1
21 quarters
1
2 3 4 5

Similar funds

ABI
Abrams Bison Investments Bethesda, Maryland $2.05B AUM 71.03% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return

Rock Springs Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Rock Springs Capital Management held 116 positions worth $2.05B, up 21% from $1.7B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Rock Springs Capital Management's Q2 2026 filing shows 16 new, 40 increased, 31 reduced and 12 closed positions. Its largest new stake was Avalyn Pharma: 662,918 shares worth $21.8M. The largest sale was argenx, an estimated $37.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Rock Springs Capital Management's largest Q2 2026 buy was Avalyn Pharma: 662,918 shares worth $21.8M.
  • Rock Springs Capital Management added most to Travere Therapeutics in Q2 2026, an estimated $31.1M increase.
  • Rock Springs Capital Management's biggest Q2 2026 reduction was argenx, cutting an estimated $37.7M.
  • Rock Springs Capital Management fully exited Arcellx in Q2 2026, selling an estimated $19.5M.
  • Rock Springs Capital Management's ten largest holdings make up 44% of its $2.05B portfolio in Q2 2026.
  • Rock Springs Capital Management opened 16 new positions and closed 12 in Q2 2026.
  • Rock Springs Capital Management's portfolio value rose 21% quarter-over-quarter to $2.05B.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.